Global Search

Hide Filters

Showing 2040 results

Press release / Dec 05, 2016

Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®

ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued…
Press release / Sep 09, 2016

New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions

NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…
Press release / Sep 28, 2015

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
Press release / Apr 27, 2015

Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL

Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most…
Press release / Jun 30, 2015

Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches

New features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments These apps…
Press release / May 21, 2016

Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals

US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto[1] Updated…
Press release / Mar 17, 2015

Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer

Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…
Ad hoc release / Oct 18, 2018

Novartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittliche Therapieplattformen voran, um das zukünftige Wachstum zu beschleunigen

Der Nettoumsatz steigt um 6% (kWk[1], +3% USD), vor allem dank folgender Beiträge: Cosentyx erzielt mit starken Volumenzuwächsen in allen Indikationen einen Umsatz von USD 750 Millionen (+37% kWk…
Press release / Jun 20, 2017

Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by…
Press release / Feb 25, 2019

Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)

Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…

‹ Previous page
1
…
19
20
21
22
23
24
25
…
204
› Next page